AlloSource

61 articles about AlloSource

• Study on Prochondrix Osteochondral Allograft Published in the Journal of Orthopaedic Surgery Demonstrates Encouraging Outcomes When Used on Isolated Articular Cartilage Defects

  6/29/2023

  AlloSource® announced the Journal of Orthopaedic Surgery published the study titled "Short term clinical outcomes of a ProChondrix® thin laser-etched osteochondral allograft for the treatment of articular cartilage defects in the knee." This study demonstrated encouraging patient-reported outcomes in the treatment of symptomatic articular cartilage lesions using a laser-etched osteochondral allograft, ProChondrix.

• Allosource Announces President and CEO Retirement

  8/2/2022

  AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their patients, announced President and CEO, Tom Cycyota, plans to retire.

• AlloSource® Adds Quadricep Tendons to Its AlloConnex™ Line of Tendons, Ligaments and Fascia

  7/12/2022

  AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their patients, announced the addition of a quadricep tendon to its AlloConnex™ line of tendons, ligaments and fascia.

• AlloSource Honors Dr. David Argo With The Annual Dr. Steven Gitelis Inspiration Award

  6/9/2021

  AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, announced it is awarding Dr. David Argo with its fifth annual Dr. Steven Gitelis Inspiration Award.

• AlloSource Announces First Patients Implanted With AlloWrap Amniotic Membrane In Clinical Study For Two-Level Anterior Cervical Discectomy And Fusion Procedures

  2/23/2021

  AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products, announced the first patients have been enrolled in its clinical study titled, A Randomized, Controlled Study to Evaluate Effectiveness of AlloWrap® Amniotic Membrane for the Reduction of Post-Operative Soft Tissue Inflammation in Two-Level Anterior Cervical Discectomy and Fusion Procedures.

• AlloSource Commits Multi-Year Financial Support to Phoenix Society for Burn Survivors

  12/22/2020

  The generous donation will support burn survivor healing through major initiatives surrounding patient and family care, virtual programming and peer support

• AlloSource Honors Dr. Ergun Kocak With The Annual Dr. Steven Gitelis Inspiration Award

  8/4/2020

  AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, announced it is awarding Dr. Ergun Kocak with its fourth annual Dr. Steven Gitelis Inspiration Award.

• AlloSource Celebrates 25 Years Of Doing More With Life

  8/9/2019

  AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, will be celebrating 25 years of honoring donors and helping patients heal through the gift of tissue donation starting Saturday.

• AlloSource Awards Dr. Matthew Provencher The Annual Dr. Steven Gitelis Inspiration Award

  5/8/2019

  AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced it is awarding Dr. Matthew Provencher with its third annual Dr. Steven Gitelis Inspiration Award

• AlloSource Hosts 25th Anniversary Event Featuring Columbine Survivor And Tissue Recipient Kacey Ruegsegger Johnson

  4/25/2019

  AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, celebrates 25 years of honoring donors and helping patients heal with an event featuring Columbine survivor and tissue recipient Kacey Ruegsegger Johnson.

• AlloSource Announces Two-Year Shelf Life On ProChondrix CR Fresh Cryopreserved Osteochondral Allograft

  3/12/2019

  AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, announced that ProChondrix® CR now has a two-year shelf life based on the results of real-time testing.

• Allosource Scientists Contribute To NASA's Jet Propulsion Laboratory Study On Antimicrobial Survivability On The International Space Station

  12/10/2018

  AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, served as a contributing science team to NASA's Jet Propulsion Laboratory's (JPL) scientific study on further antimicrobial survivability on the International Space Station (ISS). 

• AlloSource Granted Patent For Proprietary Laser Cutting Enclosure

  11/16/2018

  AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, received U.S. patent 10,105,793, titled Enclosure for laser cutting of human tissue.

• AlloSource Awards Dr. Kevin Shea The Annual Dr. Steven Gitelis Inspiration Award

  7/17/2018

  AlloSource announced that it will award Dr. Kevin Shea with its second annual Dr. Steven Gitelis Inspiration Award.

• AlloSource Announces Two Presentations On ProChondrix At The International Cartilage Repair Society World Congress

  4/10/2018

  AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced that clinical and scientific data on its ProChondrix® osteochondral allograft will be presented at the International Cartilage Repair Society's 14th World Congress

• AlloSource Co-Authors International Space Station Microbial Study With NASA's Jet Propulsion Laboratory

  1/17/2018

  AlloSource and NASA's Jet Propulsion Laboratory co-authored a scientific publication titled "Detection of antimicrobial resistance genes associated with the International Space Station environmental surfaces" that was published today in Nature's Scientific Reports.

• AlloSource Announces Raime Leeby Muhle as CFO

  12/15/2017

  With over 18 years of experience, Leeby Muhle's background spans from emerging high growth businesses to large and mature organizations.

• AlloSource Announces Bob Lay as COO

  11/8/2017

  With over 20 years of experience in both finance and operations, Bob has a broad-based understanding of how each department within an organization impacts another.

• AlloSource Announces Milestone In Production Of Bioengineered Blood Vessels For Humacyte's Vascular Access Phase III Clinical Trial

  9/13/2017

• Stryker And AlloSource Announce Collaboration To Distribute Biologics For Use In Sports Medicine Procedures

  5/19/2017